With Molnupiravir, Timing Is Everything

In a phase 2 trial, molnupiravir was not effective for patients with COVID-19 requiring inpatient care.

In December 2021, the nucleoside analog molnupiravir received EUA for outpatient treatment of COVID-19 based on a phase 3 study (MOVe-OUT) showing it reduced hospitalization and death by 30% (N Engl J Med 2021 Dec 16 [e-pub]). Researchers now report phase 2 results of a companion study (MOVe-IN) assessing molnupiravir's efficacy in patients ill enough to require hospitalization but without critical illness or severe respiratory failure. This international trial compared 200, 400, or 800 mg of molnupiravir or placebo twice daily for 5 days in individuals with COVID-19 for ≤10 days; those with immunosuppression, COVID-19 vaccination, or thrombocytopenia were excluded, but treatment with remdesivir, glucocorticoids, or both was permitted.

Among…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

With Molnupiravir, Timing Is Everything

Topics

Reviewing Author